Penny Powell

2 months ago | jdsupra.com | Penny Powell |Matthias Schweiger |Jodi Scott

In the EU, the AI Act has been approved, carrying significant implications for medical device, technology, and pharmaceutical firms. In the US, there is no comprehensive federal AI legislation, but at least 45 states have introduced bills that would regulate AI, with 31 having enacted such legislation.

Jan 7, 2025 | jdsupra.com | Penny Powell |Matthias Schweiger |Jodi Scott

Artificial intelligence (AI) is transforming the health care landscape, from diagnostics to drug development and clinical trials. As AI technologies rapidly evolve, global regulators face the complex task of regulating AI to ensure patient safety, while still fostering innovation.

Jan 4, 2024 | jdsupra.com | Penny Powell |Jodi Scott |Andrew Strong

January 4, 2024 Penny Powell, Jodi Scott, Andrew Strong Hogan Lovells + Follow x Following x Following - Unfollow Contact To embed, copy and paste the code into your website or blog: Cell, tissue, and gene therapies (CTGT) have for years offered the potential for truly personalized medicine for many near-incurable disease indications.

Jan 4, 2024 | lexology.com | Penny Powell |Jodi Scott |Andrew Strong

The annual J.P. Morgan Healthcare Conference (JPM) provides a unique opportunity to make connections among life sciences and health care emerging companies, pharma/biotech companies, investors, and advisors. This is an article in our “Life Sciences Transactional Insights” series, which aims to provide key practical takeaways for our transactional colleagues by anticipating the needs of their regulatory, intellectual property, and business stakeholders.

Dec 20, 2023 | jdsupra.com | Katie McConnell |Penny Powell

Earlier this year, the Commission announced a proposed new Directive and Regulation relating to medicinal products for human use (EU pharma regulatory package) followed almost simultaneously by a series of proposed new intellectual property rules with the stated goal of boosting innovation, investment, and competitiveness within the European Union single market (EU patent package).